Pain-free exercise program for people with peripheral artery disease
Tests a pain-free exercise program in people with peripheral artery disease.
Key facts
- Who runs it
- University of Oklahoma
- Where
- Oklahoma City, United StatesSee the site
- Trial code
- Registry title
- The Effects of a Novel, Non-ischemic and Pain-free Exercise Intervention in Peripheral Artery Disease
- Status
- Recruiting
- People taking part
- 100 people, planned
- Started
- 9 Sept 2024
- Expected to end
- 31 Jul 2029
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Exercise
- Record updated
- 29 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 40 or older with peripheral artery disease (narrowed leg arteries) who get leg pain when walking (claudication). They will do a 3-month supervised treadmill walking program.
- Age
- 40 years and older
- Sex
- All sexes
- Disease stage
- Peripheral artery disease with leg pain when walking (intermittent claudication), confirmed on a treadmill test. ABI (ankle-to-arm blood pressure ratio) <= 0.90 at rest, or > 20% drop in ankle blood pressure after the treadmill test. People with no symptoms (Fontaine Stage I), pain at rest (Fontaine stage III) or tissue loss (Fontaine stage IV) cannot join.
- Earlier treatment
- People who started cilostazol or pentoxifylline within three months before the study cannot join. People who had a procedure to reopen leg arteries within one month before, or during the study, cannot join.
- Biomarker or test result
- ABI <= 0.90 at rest, or > 20% decrease in ankle systolic blood pressure after exercise. ABI cannot be above 1.40.
Main reasons for not taking part
- Walking limited by a disease other than PAD
- Active cancer
- Kidney failure (stage 5 chronic kidney disease)
- Calf skin fold over 25 mm, or finger blood oxygen below 95%
- Not finishing the starting run-in phase within three weeks
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- history of claudication assessed by the Walking Impairment Questionnaire,
- ambulatory leg pain in either one or both legs consistent with intermittent claudication confirmed during a screening graded treadmill test using the Gardner-Skinner protocol,
- an ABI <= 0.90 at rest or > 20% decrease in ankle systolic blood pressure in either one or both legs immediately following the treadmill exercise test
- age >= 40 years
Who cannot take part
- use of medications indicated for the treatment of intermittent claudication (cilostazol and pentoxifylline) initiated within three months prior to investigation,
- peripheral revascularization within one month prior to investigation, or peripheral revascularization performed during the study,
- exercise tolerance limited by any disease process other than PAD,
- active cancer,
- kidney failure defined as stage 5 chronic kidney disease,
- failure to complete the baseline run-in phase within three weeks
- absence of PAD (ABI > 0.90 at rest and ankle systolic blood pressure < 20% decrease after exercise,
- inability to obtain an ABI measure due to non-compressible vessels (ABI > 1.40),
- asymptomatic PAD (Fontaine Stage I) determined from the medical history and verified during the graded treadmill test,
- rest pain due to PAD (Fontaine stage III)
- tissue loss due to PAD (Fontaine stage IV)
- a calf skin fold measurement > 25 mm, because of potential interference with the light path of the NIRS probe from penetrating the subcutaneous tissue,
- pulse arterial oxygen saturation of the index finger < 95% because of potential deleterious effect on calf muscle StO2 from poor pulmonary gas exchange, and
Where in United States
- O'Donoghue Research Building, University of Oklahoma Health Sciences CenterOklahoma City, United StatesContact: Andrew W. Gardner, Ph.D.Taking people
About the trial
What the trial wants to find out
This study is a 3-month, prospective, randomized controlled clinical trial designed to address the efficacy of the Non-Ischemic Exercise (NICE) program to improve exercise and vascular outcome measures in patients with peripheral artery disease (PAD).
The 2 groups in the trial
- Non-Ischemic Exercise (NICE) exercise programTreatment being tested
Patients will perform supervised treadmill walking for 3 months. Patients randomized to the NICE program will walk intermittently at a slow speed of approximately 1.4 mph for only 2-3 minute bouts that do not elicit claudication pain.
Treatment: Exercise
- Standard exercise programExisting treatment, for comparison
Patients will perform supervised treadmill walking for 3 months. Patients randomized to the Standard program will walk intermittently at a speed of approximately two mph to near maximal claudication pain.
Treatment: Exercise
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Effects of a Novel, Non-ischemic and Pain-free Exercise Intervention in Peripheral Artery Disease
- Plain-language title
- Pain-free exercise program for people with peripheral artery diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 29 May 2026